Tirzepatide

Dual GIP and GLP-1 receptor agonist

Fiche techniqueLZH-002

Code: GIP / GLP-1
Formule: C225H348N48O68
Masse moléculaire: 4813.5 Da
Demi-vie: ~120 h (≈ 5 days)
Voie de recherche: Subcutaneous (research)
Cibles moléculaires: GIPR · GLP-1R
Découverte / divulgation: Disclosed 2018, Eli Lilly
Pureté cible: ≥ 98 %
Conservation recommandée: −20 °C, à l'abri de la lumière. De 2 à 8 °C après reconstitution.

Synonymes

LY3298176, Mounjaro, Zepbound

Aspect

White lyophilized powder

Solubilité

Soluble in phosphate buffer pH 7-8

Séquence

YAibEGTFTSDYSIaibLDKIAQK(γE-2xOEG-C20 diacid)AFVQWLIAGGPSSGAPPPS-NH2

Analystes examinant le chromatogramme HPLC du lot en cours — FIG. 201Analytical Lab
Identity, purity and main-peak area are checked by reversed-phase HPLC against an in-house reference standard for this sequence. The chromatogram you see on the certificate of analysis is generated at this exact bench, by the analysts who release the batch.

Technicien surveillant un réacteur en acier inoxydable pendant la montée en échelle — FIG. 202Scale-up Operations
When a sequence moves from milligram research lots to multi-gram research supply, the same chemistry is transferred onto jacketed stainless reactors. Temperature, agitation and reagent equivalents are logged in real time so that the larger batch matches the analytical fingerprint of the small one.

Vue d'ensemble

Tirzepatide is the first dual GIP and GLP-1 receptor agonist, a 39 amino acid synthetic peptide that activates two incretin pathways simultaneously.

Pharmacologie et mécanisme

GIP receptor co-activation enhances insulin secretion, improves lipid metabolism and modulates adipose tissue, stacking with GLP-1 effects for stronger metabolic and body weight outcomes.